Table 6.
Adverse effects in included studies (DLM and BDQ-containing regimens group)
| Author | Number of patients | QTcF prolongation | Hepatic disorder/ Elevated liver enzyme | Renal failure/ Increased creatinine | Optic neuropathy/ Blurred vision | Ototoxicity/Hearing loss | Hematological disorders (Anemia, thrombocytopenia, eosinophilia) | Gastrointestinal symptoms (Diarrhoea, vomiting, nausea, abdominal pain) | Peripheral neuropathy | Electrolyte disturbance | Arthralgia | Psychiatric disorder | Dermatologic symptoms |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Auchynka et al., 2021 | 20 | - | - | - | - | - | - | - | - | - | - | - | - |
| Das et al., 2021 | 70 | 5 | 1 | - | - | - | - | 3 | - | - | - | - | - |
| Hafkin et al., 2019 | 84 | - | - | - | - | - | - | - | - | - | - | - | - |
| Madzgharashvili et al., 2021 | 2 | 0 | - | - | - | - | - | - | - | - | - | - | - |
| Dooley et al., 2021 | 20 | - | - | - | - | - | - | - | - | - | - | - | - |
| Kwon et al., 2021 | 28 | 17 | - | - | - | - | - | 1 | - | - | - | - | - |
| Das et al., 2020 | 12 | 1 | - | - | - | - | - | - | - | - | - | - | - |
| Lee et al., 2020 | 74 | 23 | - | 1 | - | - | - | 4 | - | - | - | - | - |
| Olayanju et al., 2020 | 40 | - | - | - | - | - | - | - | - | - | - | - | - |
| Kim et al., 2018 | 11 | 2 | - | - | - | - | - | - | - | - | - | - | - |
| Ferlazzo et al., 2018 | 28 | 4 | - | 1 | - | - | - | 1 | 1 | - | - | 2 | - |
| Kang et al., 2020 | 67 | - | - | - | - | - | - | 3 | - | - | - | - | - |
| Sarin et al., 2019 | 42 | - | - | - | - | - | - | - | - | - | - | - | - |
| Pirmahmadzoda et al., 2021 | 11 | - | - | - | - | - | - | - | - | - | - | - | - |
| Ghosh et al., 2021 | 147 | 3 | - | - | - | - | - | - | - | - | - | - | - |
QTcF: corrected QT with the Fredericia formula; DLM: delamanid; BDQ: bedaquiline